clinical trial · NCT07362888
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Solid Tumors (Phase 1)ADCE-B05
brief summary
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
started
Mar 17, 2026
primary completion
Dec 31, 2026
completion
Mar 14, 2029
last updated
Apr 15, 2026
detailed description
Safety and tolerability will be evaluated by incidence of DLTs. Efficacy will be evaluated by antitumor activity: ORR, DOR, PFR, and TTR per RECIST v 1.1
official title
A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol